SNCA and Parkinson disease: Intriguingly, despite the suggested triggering role of heavy metals in the development of PD [33], cisplatin was shown to inhibit filamentous aggregation of α-synuclein in solution [39], but the effects of this and other platinum-based antitumoral drugs in cancer survivors related to the appearance of PD have not been specifically determined.